FDA Announces Regulatory Review Period for Beqvez Following Patent Extension Request
February 06, 2026
February 06, 2026
WASHINGTON, Feb. 6 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration issued a notice establishing the regulatory review period for the human biological product Beqvez. This determination is a prerequisite for the U.S. Department of Commerce Patent and Trademark Office to process a patent term extension application submitted by the Children's Hospital of Philadelphia.
Beqvez is a gene therapy indicated for adults with moderate to severe hem . . .
Beqvez is a gene therapy indicated for adults with moderate to severe hem . . .